

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/893,033	06/27/2001	Genichi Kakefuda		3401
7590 06/03/2004			EXAMINER	
Sutherland Asbill & Brennan LLP			SAIDHA, TEKCHAND	
999 Peachtree Street N.E. Atlanta, GA 30309-3996			ART UNIT	PAPER NUMBER
•			1652	• -
		DATE MAILED: 06/03/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
	09/893,033	KAKEFUDA ET AL.					
Office Action Summary	Examiner	Art Unit					
	Tekchand Saidha	1652					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status							
1) Responsive to communication(s) filed on 25 Ja)⊠ Responsive to communication(s) filed on <u>25 January 2002</u> .						
2a) This action is FINAL . 2b) This	This action is FINAL . 2b) ☐ This action is non-final.						
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims							
4) Claim(s) 11-83 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 11-83 are subject to restriction and/or election requirement.							
Application Papers							
9) The specification is objected to by the Examiner.							
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No.							
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).							
* See the attached detailed Office action for a list of the certified copies not received.							
Attachment(s) 1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)							
Notice of References Cited (FTO-892) Interview Suffirmary (FTO-413)							

Art Unit: 1652

Election/Restrictions

- 1. Applicants preliminary amendment filed January 25, 2002 is acknowledged. Claims 1-10 have been cancelled. New claims 11-83 have been added. Claims 11-83 are subject to the following restriction requirement.
- 2. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - Claims 11-21 & 24-34 drawn to polynucleotide [SEQ ID NO : 3] encoding a mutant phytoene desaturase (pds gene) resistance to 4'-fluoro-6[(α, α, α, trifluoro-m-tolyl) oxy]-picolinamide, transgenic plant, vector and host cell, classified in class 435, subclass 189.
 - II. Claims 22-23 & 35-37, drawn to a process for selection of new traits such as herbicide resistant, classified in class 435, subclass 413.
 - III. Claims 38-48 & 52-62, drawn to a polynucleotide [SEQ ID Nos. 6 & 17], vector, host cell and transgenic plants comprising the Arabidopsis acetolactate synthase (AHAS) classified in class 435, subclass 232.
 - IV. Claims 49-51 & 63-65, drawn to a selectable marker for transformation comprising a cyanobacterial AHAS subunit, classified in class 536, subclass 23.1.
 - V. Claims 66-69, drawn to a rapid plate assay screening method designed to identify inhibitors of specific metabolic pathway, classified in class 435, subclass 69.2.
 - VI. Claims 70-75, drawn to a method to isolate and select mutants resistant to herbicide, classified in class 435, subclass 4.

Art Unit: 1652

VII. Claims 76-77, drawn to a method of improving genetic transformation of cyanobacteria, classified in class 435, subclass 6.

- VIII. Claims 78-82, drawn to a method of transforming plastomes [a genetic compliment of a plastid], classified in class 435, subclass 252.3.
- IX. Claim 83, drawn to a method of target site gene identification, classified in class 536, subclass 24.3.

The inventions are distinct, each from the other because of the following reasons:

- 3. The DNA [SEQ IDNO: 3] encoding the mutant phytoene desaturase of Group I and DNA [SEQ ID NO: 6 or 17] encoding acetolactate synthase (AHAS- larger and smaller subunits) of Group III are structurally distinct molecules encoding different enzymatic or catalytic or biological activities, are therefore patentably distinct.
- 4. Inventions I or II and III and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (M.P.E.P. □ 806.05(h)). In the instant case the DNA of Group I or III can be used in the recombinant expression of the respective proteins rather than in the process of Invention II. For the same reason Inventions I or III are distinct from Inventions IV-IX.
- 5. The DNA of Invention I or III and the selectable marker of Invention IV have differing structure and function. Therefore, these products are patentably distinct.

Art Unit: 1652

- 6. The methods of Inventions II, V-IX are related in that each method requires the use of Invention I or III. However, the steps and end points of the methods are wholly different and therefore Inventions II, V, VI, VII, VIII and IX are patentably distinct.
- 7. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.
- 8. A telephone call was made to William L. Warren on May 27, 2004 to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

9. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

10. Rejoinder

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after

Art Unit: 1652

final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312. In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re Brouwer and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder.

11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tekchand Saidha whose telephone number is (571) 272 0940. The examiner can normally be reached on 8.30 am - 5.00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy can be reached on (571) 272 0928. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1652

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Tekchand Saidha, Primary Examiner (1652)

Recombinant Enzymes, E03A61 Remsen Bld.

400 Dulany Street, Alexandria, VA

Telephone: (571) 272-0940

May 27, 2004